GlobeNewswire PharmaOriginal article
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
EarningsXDEMVYPositive
AI Analysis
Summary
Tarsus Pharmaceuticals reported second quarter 2026 XDEMVY net product sales of $173.9 million, representing a 69% year-over-year increase. The company is advancing the next phase of growth.
Financial Highlights
Revenue
$173.9 million
Importance:5/10
Sentiment:
0.70
earningsQ2 2026revenue growthXDEMVY
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 6, 2026 11:03 AM